REFRACTORINESS TO DONOR PLATELETS TRANSFUSION IN PATIENTS WITH APLASTIC ANEMIA AND HEMOBLASTOSIS

Refractoriness to transfusions of platelet concentrates (PC) adversely affects the conduct of complex therapy in hematological patients. Individual selection of platelets is recommended for such patients. In cases of high degree of alloimmunization with the formation of polyspecific antibodies, when individual selection is difficult, procedures plasmapheresis (PPs) is included in the treatment program.

Aims: to evaluate the effectiveness of PC transfusions by individual selection in patients refractory to transfusions and the use of PPs as a second line therapy in combination with individual platelet selection.

Materials and methods: from September 2015 to December 2017, 91 patients with refractory to PC transfusions from 1263 patients who received PC transfusion were observed in the center’s clinics. The median age was 43 (18–71) years. M/F – 38/53. Patients: 20 – aplastic anemia (AA), 17 – myelodysplastic syndrome (MDS), 45 – acute myeloid leukemia (AML), 9 – acute lymphoblastic leukemia (ALL). All patients underwent PC transfusion by individual selection (HLA/HPA) Immucor’s Capture-P solid phase technology. In 28 (30 %) of 91 patients, due to the inability to select, there was a need for PP as a second line therapy. Patients: AA – 4 (20 %); MDS – 8 (47 %); AML – 12 (26 %); ALL– 4 (44 %). The median age was 48 (23–71) years. M/F – 8/20. From 2 to 15 procedures were performed (on average – 6) for each patient. All patients received PC transfusions by individual selection by cross-matching immediately after the PP procedure. The efficacy of PC transfusions was assessed by Absolute Platelet Increment (API) and Corrected Count Increment (CCI), relief of hemorrhagic syndrome.

Results: in 26 of 28 refractory to PC transfusions patients, in the absence of compatible donor platelets, carrying out PPs in combination with subsequent individual platelet selection promoted relief of hemorrhagic syndrome, increase in API from 3.3 × 109/L at 29.5 × 109/L and CCI from 1.3 to 10.7. Against the background of PPs, combined with individual selection, the degree of alloimmunization (the percentage of incompatible pairs) decreased on average: AA (n = 4) – from 91.7 to 50.2 %; MDS (n = 8) – from 89.6 to 31.6 %; AML (n = 12) – 86.0 to 40.5 % and ALL (n = 4) – from 91.7 to 37.7 %. In 2 patients with a high degree of alloimmunization and after carrying out PPs, it was not possible to select compatible platelets, PC transfusions were ineffective (API = 5 × 109/L, CCI = 1), and hemorrhagic syndrome was not completely managed, but its severity was reduced.

Conclusions. With the development of refractoriness to PC transfusions and the ineffectiveness of individual platelet selection, PPs should be used as the second line of therapy, which, combined with individual selection, increases the likelihood of compatible donor-recipient pairs and increases the clinical efficacy of PC transfusions. When PPs is ineffective in combination with individual selection, it is necessary to exclude the syndrome of increased consumption and other mechanisms of refractoriness.

1. Schiffer C.A., Bohlke K., Delaney M., et al. Platelet Transfusion for Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 2018;36(3):283–99. DOI: 10.1200/JCO. 2017.76.1734.PMID: 29182495.

2. Hod E., Schwartz J. Platelet transfusion refractoriness. Br J Haematol 2008;142(3):348–60.DOI: 10.1111/j.13652141.2008.07189.x16. PMID: 18510692.

3. Zotikov E.A., Babaeva A.G., Golovkina L.L. Platelets and antiplatelet antibodies. Мoscow: Monolit, 2003; 128 p. (In Russ.).

4. Golovkina L.L. Genetic restrictionof humoral immune response. Onkogematologiya = Oncohematology 2014;9(2):58–62 (In Russ.).DOI: 10.17650/1818-8346-2014-9-2-58-64.

5. Golovkina L.L., Zotikov E.A. Alloimmunization to HPA and HLA antigens in hematological patients with multiple blood components transfusions. Novoe v transfusiologii = New in Transfusiology 2003; 34:12–22 (In Russ.).

6. Wallington T. Essential immunology for transfusion medicine. In: Murphy M., Pamphilon D. Practical Transfusion Medicine. London: Blackwell Publishing Ltd., 2009. P. 7–18.

7. Mineeva N.V., Gavrovskaya S.V., Krobinets I.I. et al. Frequency of erythrocytic, leukocytic and platelets alloantibodies in patients with hematological diseases. Onkogematologiya = Oncohematology 2013;8(4):13–7 (In Russ.). DOI: 10.17650/1818-8346-2013-8-4-13-17.

8. Mineeva N.V., Krobinets I.I., Blinov M.N., Kapustin S.I. Platelet antigens and antibodies. Literature review. Onkogematologiya = Oncohematology 2013;8(3):60–8. (In Russ.). DOI: 10.17650/1818-8346-2013-8-3-60-68.

9. Glazanova T.V., Rozanova O.E., Pavlova I.E. et al. Effect of hemocomponent therapy on immunity parameters and alloantibodies formation in patients with aplastic anemia. Vestnik gematologii = Bulletin of Hematology 2015;11(3):4–8 (In Russ.).

10. Golovkina L.L. Platelet antigens and their medical significance. Gematologiya i transfusiologiya = Hematology and Transfusiology 2010;4:24–31 (In Russ.).

11. Manis J.P., Silberstein L.E. Platelet refractoriness: It’s not the B-all and endall. Blood 2016;127(14):1740–1. DOI: 10.1182/blood-2016-02-695437. PMID: 27056995.

12. Brouk H., Bertrand G., Zitouni S. et al. HPA antibodies in Algerian multitransfused patients: Prevalence and involvement in platelet refractoriness. Transfus Apher Sci 2015;52(3):295–299. DOI: 10.1016/j.transci.2014.12.028. PMID: 25620758.

13. Krasnikova N.A., Poreshina L.P., Golovkina L.L., Zotikov E.A. Identification of antiplatelet antibodies in patients with thrombocytopenia. Novoe v transfusiologii = New in Transfusiology 1999;24:44–9 (In Russ.).

14. Jia Y., Li W., Liu N., et al. Prevalence of platelet-specific antibodies and efficacy of crossmatch-compatible platelet transfusions in refractory patients. Transf Med 2014;24(6):406–10. DOI:10.1111/tme.12157. PMID: 25327352.

15. Golovkina L.L., Kut’ina R.M., Zotikov E.A. et al. The effect of plasmapheresis in combination with platelet transfusions on antiplatelet antibodies activity. Novoe v transfusiologii = New in Transfusiology 2001;29:57–65 (In Russ.).

16. Golovkina L.L., Kut’ina R. M. Zotikov E.A. The effect of plasmapheresis on antiplatelet antibodies activity. Klinicheskaya laboratornaya diagnostika = Clinical laboratory diagnostics 2002;4:54–5 (In Russ.).

17. Szczepiorkowski Z.M., Winters J.L., Bandarenko N. et al. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence-Based Approach from the Apheresis Applications Committee of the American Society for Apheresis. J Clin Apher 2010;25(3):83–177. DOI: 10.1002/jca.20240. PMID: 20568098.

18. Kalinin N.N. Clinical application of extracorporeal methods of treatment. Moscow: Trekpor technology, 2006. 168 p. (In Russ.).

19. Mikhailova E.A., Yadrikhinskaya V.V., Vernyuk M.A. et al. Plasmaand lymphocytopheresis in complex therapy of aplastic anemia. In: Proceedings of the 8th conference of the Moscow society of hemapheresis. Moscow, 2000. P. 39–40 (In Russ.).

20. Forest S.K., Hod E.A. Management of the Platelet Refractory Patient. Hematol Oncol Clin North Am 2016;30(3):665–77. DOI: 10.1016/j.hoc.2016.01.008. PMID: 27113003.

21. Rachel J.M., Sinor L.T., Tawfic O.W., et al. A solid phase red cell adherence test for platelet cross-matching. Med Lab Sci 1985;42(2):194–5. PMID: 4068931.

22. Heal J.M., Blumberg N., Masel D. An evaluation of crossmatching, HLA, and ABO matching for platelet transfusions to refractory patients. Blood 1987;70(1):23–30. PMID: 3474041.

23. Ayupova R.F., Sultanbaev U.S., Zhiburt E.B. Effectiveness of multiple platelet transfusion. Gematologiya. Transfuziologiya. Vostochnaya Evropa = Hematology. Transfusiology. Eastern Europe 2017;391:30–7 (In Russ.).

24. Karpova O.V., Roitman E.V., Ignatova A.A. et al. Evaluation of the quality of platelet concentrate harvested by the apheresis method with the use of a pre-bath SSP+ solution. Voprosy gematologii/onkologii i immunopatologii v pediatrii = Pediatric Hematology/Oncology and Immunopathology 2014;13(2):20–4 (In Russ.).

25. Kiefel V. Reactions Induced by Platelet Transfusions. Transfus Med Hemother 2008;35(5):354–8. DOI:10.1159/000151350. PMID: 21512624.